MYO
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a low multiple of sales, but lacks the earnings to support a traditional valuation.
- Low P/S ratio (0.75)
- No P/E due to lack of earnings
- P/B of 2.68 is high for a distressed company
- Graham Number unavailable due to negative earnings
Growth metrics are trending downward across all primary indicators.
- High gross margins provide a theoretical path to profitability
- Negative YoY and Q/Q revenue growth
- EPS growth is -800%
Long-term price performance is catastrophic.
- Some historical earnings beats
- 1-year return of -82.9%
- 5-year return of -91.9%
Fundamental health is critical; F-Score indicates a high probability of continued decline.
- Current ratio > 3.0
- Piotroski F-Score 1/9
- Debt/Equity of 1.70
- Negative operating margins
Non-dividend paying growth/distressed stock.
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MYO and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MYO
Myomo, Inc.
Primary
|
-91.9% | +46.4% | -82.9% | -17.9% | +23.8% | -3.3% |
|
NEPH
Nephros, Inc.
Peer
|
-63.0% | +102.8% | +42.6% | -46.5% | -1.4% | +3.6% |
|
EKSO
Ekso Bionics Holdings, Inc.
Peer
|
-91.1% | -64.0% | +54.0% | +66.6% | -27.2% | -18.0% |
|
CCEL
Cryo-Cell International, Inc.
Peer
|
-52.6% | -3.2% | -34.1% | -15.6% | +23.6% | +6.7% |
|
BTAI
BioXcel Therapeutics, Inc.
Peer
|
-99.8% | -99.6% | -30.1% | -56.4% | -37.0% | -18.7% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MYO
Myomo, Inc.
|
BEARISH | $30.5M | - | -86.2% | -38.1% | $0.79 | |
|
NEPH
Nephros, Inc.
|
BEARISH | $30.66M | 26.18 | 12.7% | 6.4% | $2.88 | Compare |
|
EKSO
Ekso Bionics Holdings, Inc.
|
BEARISH | $31.11M | - | -107.6% | -91.4% | $8.73 | Compare |
|
CCEL
Cryo-Cell International, Inc.
|
BEARISH | $29.56M | - | -% | -8.5% | $3.67 | Compare |
|
BTAI
BioXcel Therapeutics, Inc.
|
BEARISH | $29.51M | - | -% | -% | $1.09 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-14 | FEBBO WILLIAM J | Director | Stock Award | 45,000 | - |
| 2026-04-10 | GUDONIS PAUL R | Chief Executive Officer | Stock Award | 19,395 | - |
| 2026-04-10 | GUDONIS PAUL R | Chief Executive Officer | Stock Award | 16,666 | - |
| 2026-04-10 | HENRY DAVID A | Chief Financial Officer | Stock Award | 12,500 | - |
| 2026-03-16 | GETZ HEATHER C | Director | Purchase | 20,000 | $13,972 |
| 2026-03-13 | KIRK THOMAS F | Director | Purchase | 72,000 | $51,113 |
| 2026-03-12 | GETZ HEATHER C | Director | Purchase | 70,000 | $50,960 |
| 2026-01-12 | GUDONIS PAUL R | Chief Executive Officer | Stock Award | 11,637 | - |
| 2026-01-12 | HENRY DAVID A | Chief Financial Officer | Stock Award | 8,727 | - |
| 2025-11-21 | KIRK THOMAS F | Director | Purchase | 7,437 | $5,355 |
| 2025-11-19 | CROWLEY THOMAS ALOYSIUS JR | Director | Purchase | 4,385 | $3,233 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning MYO from our newsroom.